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Abstract 
Objective: The prognostic role of EEG during and after targeted temperature management 
(TTM) in post-cardiac-arrest patients, relatively to other predictors, is incompletely known. We 
assessed performances of EEG during and after TTM towards good and poor outcome, along 
with other recognized predictors. 
 
Design: Cohort study (April 2009 - March 2016). 
 
Setting: Two academic hospitals (CHUV, Lausanne, Switzerland; Mayo Clinic, Rochester, MN). 
 
Patients: Consecutive comatose adults admitted after cardiac arrest, identified through 
prospective registries. 
 
Interventions: All patients were managed with TTM, receiving pre-specified standardized 
clinical, neurophysiological (particularly, EEG during and after TTM), and biochemical 
evaluations. 
 
Measurements and Main Results: We assessed EEG variables (reactivity, continuity, 
epileptiform features, and pre-specified “benign” or “highly malignant” patterns based on the 
ACNS nomenclature), and other clinical, neurophysiological (SSEP) and biochemical 
prognosticators. Good outcome (Cerebral Performance Categories 1 and 2) and mortality 
predictions at three months were calculated. Among 357 patients, early EEG reactivity and 
continuity, and flexor or better motor reaction had >70% positive predictive value for good 
outcome; reactivity (80.4%, 95%CI: 75.9-84.4%) and motor response (80.1%, 95%CI: 75.6-
84.1%) had highest accuracy. Early “benign” EEG heralded good outcome in 86.2 % (95% CI: 
79.8%-91.1%). False-positive rates (FPR) for mortality were <5% for epileptiform or 
nonreactive early EEG, nonreactive late EEG, absent SSEP, absent pupillary or corneal reflexes, 
presence of myoclonus, and NSE >75 µg/l; accuracy was highest for early EEG reactivity 
(86.6%, 95%CI: 82.6-90.0). Early “highly malignant” EEG had an FPR of 1.5 % with accuracy 
of 85.7% (95% CI: 81.7%-89.2%). 
 
Conclusions: This study provides Class III evidence that EEG reactivity predicts both poor and 
good outcome, and motor reaction good outcome after cardiac arrest. EEG reactivity seems to be 
the best discriminator between good and poor outcomes. Standardized EEG interpretation seems 
to predict both conditions during and after TTM. 
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Clinicians are increasingly confronted with expectations to provide early, reliable risk 
stratification of outcome in comatose patients after cardiac arrest (CA). Current 
recommendations emphasize the need of a multimodal approach [1-3], where available 
prognosticators target identification of poor outcome patients [4]. There is therefore an important 
need to learn about the value of readily available tools orienting towards good outcome.  
Electroencephalography (EEG) represents one of the most frequently used prognosticators [5]. 
Several groups have repetitively highlighted its value for prediction of poor prognosis [6-15]. In 
addition, some studies have highlighted that background continuity [6, 16, 17] and reactivity [18] 
can identify patients with good outcome. However, these analyses did not systematically 
examine the role of early versus late (after return to normothermia and off sedation) features, nor 
the place of EEG in comparison with other predictors. 
We aimed to explore the role of specific EEG features for good and poor outcome 
prognostication, and to compare it to the performance of other predictors, considering both early 
and later assessments. Furthermore, we intended to validate a recently proposed EEG scoring 
system [14], based on the American Clinical neurophysiology Society (ACNS) EEG 
nomenclature [19]. 
 
Methods  
Design, patients, and settings 
This cohort study includes consecutive adults (>18 years) receiving TTM in the ICU for 
hypoxic-ischemic encephalopathy following CA, with both early (during targeted temperature 
management, TTM) and late (after return to normothermia and off sedation, 48-72 hours after 
admission) EEG, and functional outcome at three months. Only subjects with missing EEG data 
were not included. Patients were identified through existing, prospective registries of the CHUV, 
Lausanne Switzerland, between April 2009 and March 2016, and the Mayo Clinic, Rochester, 
MN, between November 2009 and March 2014, approved by their IRB; consents were waived 
(no intervention).  
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Procedures and variables 
All patients received 24 hours TTM: mild hypothermia to 33-34°C [20], or controlled 
normothermia at 36°C [21], under standard sedation. At the CHUV, midazolam (0.1 mg/kg/h) or 
propofol (less frequently; 2-3 mg/kg/h), and fentanyl (1.5 µg/kg/h) infusions were given during 
the first 24-36 hours; curare was administered for shivering. At the Mayo Clinic, the protocol 
comprised midazolam infusions (0.015 mg/kg/h) or alternatively, propofol (1-2 mg/kg/h). 
Fentanyl was perfused up to 1 µg/kg/h. Curare was given as needed. Patients with myoclonus or 
EEG seizures were treated with nonsedating anticonvulsants (valproate, levetiracetam). 
Video-EEGs (CHUV: Viasys, Madison, WI; Mayo clinic: XLTEK, Pleasanton, CA) using 21 
electrodes according to the 10–20 system were performed continuously for 24-48 hours, starting 
as soon as possible after CA, or over 20-30 minutes during the first 9-30 hours and thereafter, 
within 72 hours after return to normothermia and off sedation. In both approaches, scoring was 
performed during and after TTM and sedation weaning, at the times of reactivity assessment, 
tested by applying repetitive auditory, visual, and nociceptive stimuli (finger compression, 
bilateral nipple pinching if no reactivity seen before) [12, 15]. EEG were categorized by certified 
interpreters (AOR, DFTQ, JN, JWB) for the presence/absence of 3 dichotomous features: 
reactivity (recognizable background with reproducible changes in amplitude or frequency within 
1-2 seconds of any stimulation, excluding SIRPIDs [22, 23], and muscle artifacts); spontaneous 
discontinuous pattern (suppressions of at least 10% of the recording [19]); repetitive epileptiform 
activity (periodic or rhythmic spikes, sharp waves, or spike-waves [9, 24] occurring at least over 
10% of the record). Scoring, blinded to outcome, was prospective at the CHUV and retrospective 
at the Mayo Clinic. For this study, recordings performed before 2013 were rescored to comply 
with the ACNS nomenclature [19] (that was used since then), using registries’ data and analysis 
of raw traces in unclear situations (<5%, especially for continuity). A distinction between burst-
suppression and discontinuity was not definitely retrievable in all cases without epileptiform 
components, but suppression <10 μV was identified as “flat recording”, and reactivity scoring 
did not change across time. 
Within 96 hours from CA, at normothermia and off sedation, patients were serially examined; 
best results were considered for this analysis. Pupillary and corneal reflexes were categorized as 
present vs. bilaterally absent; response to pain as flexion or better vs. extension or none [3]. 
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Early myoclonus was considered if appearing within 24 hours after sedation discontinuation. 
After TTM, cortical responses of somatosensory evoked potentials (SSEP) were categorized as 
present vs. bilaterally absent. Serum neuron-specific enolase (NSE) was measured within the 
first 72 hours, and assessed through automated immunofluorescent assays (Thermo Scientific 
Brahms NSE Kryptor®, Hennigsdorf, Germany); results of peak values were categorized using a 
threshold of 75 µg/l [15]. 
Decision to withdraw ICU support was made by interdisciplinary consensus within 10 days after 
CA, according to a pre-specified multimodal approach [9]. Importantly, early EEG scoring was 
not used for this decision.  
 
Data collection and outcome assessment 
Demographic and clinical variables were collected prospectively using Utstein’s 
recommendations [25]; CA etiology was dichotomized as cardiac vs. non-cardiac, and initial 
heart rhythm as ventricular fibrillation or tachycardia vs. asystole or pulseless activity. At the 
CHUV, time to return of spontaneous circulation was estimated on patient’s admission. Best 
neurological outcome within 3 months was assessed blinded to clinical results: at the CHUV 
prospectively through a telephone interview, at the Mayo Clinic through charts review (patients 
were routinely seen at 3 months), using Cerebral Performance Categories (CPC) [26]; CPC 1-2 
defined good recovery [4]. 
Statistics 
Contingency tables were tested through Fisher exact or chi square tests, and normally distributed 
variables with two-tailed t-tests, as needed. Two outcomes were considered: good functional 
outcome (CPC 1-2) and mortality. Sensitivity and positive predictive values (PPV) were 
calculated for good outcome, and sensitivity and false positive rates (FPR, 1-specificity) for 
mortality [4]. Accuracies (true negatives and positives / all patients) were calculated for variables 
with positive PPV of >70% for good outcome and FPR < 5% for mortality, with 95% confidence 
intervals (binomial distribution). We tested separately PPV for good outcomes considering 
“benign EEG patterns” (continuous, not suppressed background with reactivity, without 
epileptiform discharges), and FPR for mortality considering “highly malignant patterns” 
(suppression or burst-suppression, with or without periodic discharges), as recently defined [14] 
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using the ACNS nomenclature [19]. Backward stepwise logistic regression analyses were 
conducted using variables with PPV of >70% for a good outcome, or FPR < 5% for mortality, 
adjusted for treating centers; calibration was assessed with a Hosmer-Lemeshow test. 
Calculations were performed using STATA software, version 12 (College Station, TX, USA).   
 
Results 
We studied 260 patients at the CHUV (134 overlapping with [15]) and 97 at the Mayo Clinic (62 
overlapping with [27]); at 3 months, 180 (50.4%; 88.2% of survivors) had a good outcome, 24 
(6.7%) with CPC 3, and 153 (42.9%) died; nobody had a CPC 4. Included patients represent 
about 80% of those treated with TTM in the study period. Table 1 illustrates their characteristics. 
Patients at the Mayo Clinic tended to present more frequently with shockable rhythms; all had 
continuous EEG (institutional protocol). A CHUV subgroup was treated targeting 36°C, while 
all other patients received hypothermia to 33°C. CHUV patients had more often nonreactive and 
discontinuous EEGs, while early epileptiform features were more frequent at the Mayo Clinic. 
Although outcomes did not differ statistically, they had a tendency to be better at the Mayo 
Clinic; accordingly, absent pupillary reflexes or motor reactions to pain were more frequent at 
the CHUV. Time to return of spontaneous circulation at the CHUV was 23.8 ± 19.0 min; the first 
EEG including reactivity assessment was performed 17.9 ± 6.2 hours after CA (in 236 patients, 
91%, within 24 hrs).  
Table 2 summarizes predictive performances for good outcome (CPC 1-2). Three variables 
showed a PPV >70%: early EEG reactivity and continuity, and flexor or better motor response. 
All features had sensitivities >80%; EEG reactivity and motor reaction showed the highest 
accuracy. The multivariable logistic regression confirmed that the three were independently 
related to favorable prognosis (Table 3a). Early and late “benign” EEG had also high PPV.  
Table 4 shows mortality prediction (suppl. Tables: stratification between previously published 
and new patients). Several variables had an FPR <5%; while sensitivity was below 50% for 
nearly all, EEG reactivity stood out (especially early EEG, displaying the highest accuracy). 
Early and late “highly malignant EEG” also showed very low FPR. Multivariable analysis 
identified early EEG reactivity and epileptiform discharges, and late EEG reactivity, as 
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independently related to mortality (Table 3b). Figure 1 illustrates the predictive performance of 
the principal variables towards the two main outcomes.  
 
Discussion 
Several studies evaluated predictors of poor prognosis after CA, but our analysis is one of the 
few also assessing indicators of good outcome, and explores prognosticators during and after 
TTM in relation to both outcomes. It shows that EEG reactivity during TTM and sedation has the 
highest accuracy for both good and poor outcome. It also highlights the prognostic value for 
good outcome when the motor response to pain is flexion or better. Furthermore, a predefined 
“benign” EEG background [14] has a high PPV for good outcome, while a “highly malignant” 
pattern [14] has a very low FPR for mortality, both during and after TTM.  
EEG reactivity 
During TTM, reactivity seems the most robust discriminator between good and poor outcome, 
and is independently related to them. Reactivity during TTM correlates with neuronal injury 
reflected by NSE [12]. While mild therapeutic hypothermia should not exert a major impact on 
EEG [28], pharmacological sedation may influence background continuity [6, 15, 16]. 
Epileptiform features, which indeed do not significantly correlate with neuronal injury markers 
[12], showed lower sensitivity for mortality as compared to reactivity, and lower specificity for 
good outcome. We recognize that reactivity has an imperfect interrater reliability [29, 30], with a 
heterogeneous prevalence at our two centers, even if both are familiar with the stimulus type 
(nipples pinching) that seems to be most sensitive [31].   
Timing of EEG assessment 
EEG has been traditionally used after TTM and off sedation [9, 10, 32]: lack of reactivity 
forecasts unfavourable prognosis [9, 10], similarly to low voltage (<20 µV), suppressed or burst-
suppressed background [6, 14], or burst-suppression with identical bursts [8]. Epileptiform 
features were also related to poor outcome [9]. These features are found in current prognostic 
recommendations [1].  
9 
 
Recently, increasing attention was directed towards EEG recorded during TTM and sedation 
[24]: suppressed or low-voltage background shows higher correlation with poor outcome [6, 16, 
33, 34], similarly to lack of reactivity [11, 15], and epileptiform features [12, 13, 34]. 
Additionally, and innovatively [4], EEG has been reported to herald good outcome if a 
continuous background and normal voltage are seen at 12-24 hours [6, 16], or showing 
reproducible reactivity [18]. It is possible that recordings performed early after CA and 
standardized conditions may be exposed to less confounders (co-morbidities such as infections, 
vigilance, and co-medications).  
This study validates recent findings of the TTM-trial EEG analysis [14] on pre-defined “benign” 
and “highly malignant patterns”, confirming the robustness of prediction for poor and good 
outcome after return of normothermia, albeit with slightly higher FPR, probably reflecting a less 
standardized reading and the considerably greater number of patients, better corresponding to 
real clinical practice. Additionally, we expanded the usefulness of this approach into recordings 
obtained during TTM and sedation.  
Comparison with previous studies on clinical EEG 
The CHUV reactivity analyses [11, 18] were single-center, including 90 patients, with only few 
other predictors. The Mayo Clinic study [17], including 54 patients, did not evaluate other 
variables, and assigned EEG into one of three predefined categories, preventing more granular 
analyses. The Yale series [6] included 100 patients, and did not consider biochemical markers or 
SSEP. The Belgian assessment [33] involved 92 patients, also used a composite EEG scoring, 
and did not analyze in detail EEG after sedation, nor other prognosticators. A study from 
Pittsburgh on EEG counterparts of myoclonus included 65 patients; it did not report on a 
multimodal approach [34]. The Dutch 2-centers cohort was large (277 patients); however, EEG 
scorings were also composite, and EEG reactivity, corneal reflexes, or NSE were not addressed. 
Finally, the TTM trial analysis [14], with 103 subjects from European hospitals, was limited to 
normothermia, not confirming the value of low voltage [6, 16]; other prognosticators were not 
addressed. Quantitative EEG receives growing interest  [29, 35], but this approach is still limited 
by generalizability [4]. 
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While our study appears in line with these previous findings, it adds new information. It includes 
the largest number of patients, from two relatively heterogeneous cohorts in terms of EEG 
recordings, CA types, sedation, TTM, and neurophysiological, clinical and biochemical features 
(Table 1), in distinct locations with different practical approaches. This should reinforce 
generalizability of the findings. It validates outside a rigid study setting not only a recently 
proposed EEG scoring following the ACNS nomenclature [14, 30, 36], but it also analyzes core 
EEG features (reactivity, continuity and epileptiform transients), allowing detailed understanding 
of the prognostic role of each for both poor and, importantly, good outcome. Both sites used a 
pre-defined protocol for discontinuation of ICU measures, rendering identification of items 
potentially biased by the self-fulfilling prophecy more straightforward [4].  
Motor reaction 
The remarkable prognostication performance of responses better than extension for identification 
of good prognosis may appear somewhat surprising. Extension or lack of movements was found 
to forecast poor prognosis before the hypothermia era [3], but was strongly questioned after 
convergent reports of unacceptable high FPRs in patients undergoing TTM (and sedation) [9, 37-
39]: it is thus not mentioned in current recommendations [1], and false positivity is high (15.2%) 
in this study. Our results indicate that a flexor or better reaction shortly after TTM independently 
heralds favourable outcome in a significant proportion of patients, confirming a previous 
observation [6]. This may represent a revival of this clinical sign to specifically detect favourable 
recovery, in a context where nearly all prognosticators are directed towards identification of poor 
prognosis.   
Limitations 
First, EEG scoring occurred prospectively at the CHUV but retrospectively -albeit blinded- at the 
Mayo Clinic; this may explain some heterogeneity of findings. Second, we included both 
continuous and routine EEG recordings. Some groups advocate continuous EEG [6, 16] as 
electrical activity evolves and seizures may be detected [7]. This technique is however not likely 
to be widely available, and routine EEGs, including stimulations for reactivity, seem to offer 
comparable information [40], at lower costs [27]. Third, EEG assessment times were not strictly 
uniform, and prevalence of EEG reactivity and continuity, brainstem reflexes, and motor 
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reaction, differed across centers. Although heterogeneous data ascertainment is possible, this 
reflects the observational design with different sedation policies (higher doses at CHUV), and 
patients’ profile (somewhat worse outcome at CHUV). Our findings may thus be generalizable to 
other settings. Moreover, multivariable models were adjusted for centers; patients at CHUV had 
worse outcomes on the raw data, but had higher chance of good outcome in the analysis adjusted 
for poor prognostic features. Reasons for this discrepancy are unclear, and may in part reflect the 
subjectivity of the CPC, which nevertheless is validated. Importantly, the difference between 
centres was significant but almost marginal (CI approaching 1), and mortality was not different. 
Fourth, several EEG items related to the ACNS-nomenclature were inferred retrospectively for 
records preceding 2013; due to this, low voltage >10µV was not systematically considered as 
incompatible with “benign”, as opposed to [14]; “highly malignant” or “benign” patterns were 
also scored retrospectively, but blinded from the outcome. It is possible that this generated some 
errors, but it seems unlikely that these were systematic. Fifth, we did not analyze brain imaging, 
used unsystematically. Sixth, outcome assessment was not uniform, and occurred at three (but 
not six) months, reflecting the centers’ practices in those years. Finally, although cause of death 
and decisions to withdraw life support were not specifically recorded, the latter were always 
discussed after clinical examinations off sedation, and EEG scoring occurred blindly towards 
outcome; therefore, despite having being available to clinicians, early EEG is unlikely to have 
been affected by the self-fulfilling prophecy.  
Conclusion 
It is of outmost importance to always formulate a prognosis after carefully evaluating all 
available information from different sources, in order to minimize risks of false poor prediction 
[1, 2, 4]. While current guidelines still rely on relatively late EEG [1, 3], early EEG represents a 
valuable tool to identify patients both with good and poor prognosis. Thus, information provided 
by EEG has important practical implications, but should never be used alone for prognostication.   
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Table 1: Clinical characteristics of the two cohorts (if no denominator is given, all patients were 
tested).   
Table 2: Predictors of good outcome in the whole cohort. 
Table 3. A: multiple logistic regression of predictors of good outcome with PPV >70%, and B: 
of predictors of mortality with FPR <5%, controlling for treating center.  
Table 4: Predictors of mortality in the whole cohort. 
Suppl. Table: Subset of mortality predictors according to previously and newly published 
patients. 
 
Figure 1: Accuracy towards good outcome (grey bars) and mortality (black bars) of predictors 
with a positive predictive value >70% for good outcome and false positive rate <5% for 
mortality.  
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Table 1: Clinical characteristics of the two cohorts (if no denominator is given, all patients were 
tested).   
Variable CHUV  
260 pts 
Mayo  
97 pts 
P (test) 
Age, years, mean (±SD) 61.8 (±14.5) 61.2 (±11.3) 0.710   (t) 
Male gender (%) 187 (71.9%) 68 (70%) 0.735  (χ2) 
Non-cardiac cause (%) 61 (22.5%) 14 (14.4%) 0.062 (χ2) 
Asystole or pulseless electrical activity (%) 94 (36.1%) 13 (13.4%) <0.001 (χ2) 
TTM with 36°C target (all others: 33°C) 27 (10.4%) 0 (0%) 0.001 (Fisher) 
Continuous EEG monitoring 41 (15.8%) 97 (100%) <0.001 (χ2) 
Early EEG not reactive 93 (35.8%) 18 (18.6%) 0.002 (χ2) 
Early EEG not continuous 139 (53.5%) 22 (22.7%) <0.001 (χ2) 
Early EEG epileptiform 45 (17.3%) 36 (37.1%) <0.001 (χ2) 
Early EEG “benign” 105 (40.3%) 54 (55.7%) 0.010 (χ2) 
Early EEG “highly malignant” 89 (34.2%) 19 (19.6%) 0.007 (χ2) 
Late EEG not reactive 82 (31.5%) 15 (15.5%) 0.002 (χ2) 
Late EEG not continuous 97 (37.3%) 9 (9.3%) <0.001 (χ2) 
Late EEG epileptiform 67 (25.8%) 30 (30.9%) 0.330 (χ2) 
Late EEG “benign” 132 (50.8%) 62 (63.9%)  0.027 (χ2) 
Late EEG “highly malignant” 84 (32.3%) 15 (15.5%) 0.002 (χ2) 
Bilaterally absent SSEP 55/244 (22.5%) 6/16 (37.5%) 0.171 (χ2) 
Bilaterally absent pupillary reflex 48/258 (18.6%) 6/97 (6.2%) 0.004 (χ2) 
Motor GCS <3 125 (48.1%) 33 (34.0%) 0.017 (χ2) 
NSE ≥75µg/l 48/233 (20.6%) 13/96 (13.5%) 0.134 (χ2) 
Good CPC at 3 months (1-2) (%) 124 (47.7%) 56 (57.7%) 0.091 (χ2) 
Mortality (%) 118 (45.4%) 35 (36.1%) 0.114 (χ2) 
CPC= cerebral performance category; NSE = neuron specific enolase; SSEP = somatosensory evoked 
potentials; TTM= targeted temperature management. For “benign” and “highly malignant” EEG 
definitions, please see text. 
 
Table 2: Predictors of good outcome in the whole cohort. 
  Distribution Good Outcome 
(CPC 1-2) 
Accuracy 
Variable Tested  
patients 
TP FP FN TN Sensitivity 
(%) 
95% CI 
(%) 
PPV 
(%) 
95% CI 
(%) 
Point 
Est. 
95% CI 
(%) 
Age < 65 357 118 75 62 102 65.6 58.1-72.5 61.1 53.9-68.1   
Cardiac etiology 357 152 130 27 48 84.9 78.8-89.8 53.9 47.9-59.8   
Shockable rhythm 357 150 100 30 77 83.3 77.1-88.5 60.0 53.6-66.1   
Early EEG reactive 357 178 68 2 109 98.9 96.0-99.9 72.4 66.3-77.9 80.4 75.9-84.4 
Early EEG continuous 357 144 42 36 135 80.0 73.4-85.6 77.4 70.7-83.2 78.2 73.5-82.3 
Early EEG not epileptiform 357 175 101 5 76 97.2 93.6-99.1 63.4 57.4-69.1   
Early EEG “benign” 357 137 22 43 155 76.1 69.2-82.1 86.2 79.8-91.1 81.8 77.4-85.7 
Late EEG reactive 357 179 81 1 96 99.4  96.9-99.9 68.9 62.8-74.4   
Late EEG continuous 357 168 83 12 94 93.3 88.6-96.5 66.9 60.7-72-7   
Late EEG not epileptiform 357 173 87 7 90 96.1 92.2-98.4 66.5 60.4-72.3   
Late EEG “Benign” 357 163 31 17 146 90.6 85.3-94.4 84.0 78.1-88.9 86.5 82.6-89.9 
SSEP present 260 119 80 0 61 100 97.0-100 59.8 52.6-66.7   
Pupillary normal 355 177 124 3 51 98.3 95.2-99.7 58.8 53.0-64.4   
Corneal normal 354 175 104 5 70 97.2 93.6-99.1 52.7 56.8-68.4   
Motor GCS ≥3 357 151 42 29 135 83.9 77.7-88.9 78.2 71.7-83.8 80.1 75.6-84.1 
No early myoclonus 357 176 113 4 74 97.8 94.4-99.4 60.9 55.0-66.6   
NSE <75 µg/l 329 169 99 0 61 100 97.8-100 63.1 57.0-68.9   
TP= true positive, FP= false positive, FN= false negative, TN= true negative. CPC= cerebral 
performance category; SSEP= somatosensory evoked potentials; GCS= Glasgow Coma Score; 
NSE= neuron specific enolase. Accuracies were only calculated for items with PPV >70%. 
 
 
Table 3. A: multiple logistic regression of predictors of good outcome with PPV >70%, and B: 
of predictors of mortality with FPR <5%, controlling for treating center.  
A OR 95% CI P 
Early EEG reactive 39.68 9.01-175.43 <0.001 
Early EEG continuous 3.80 1.5877.75 <0.001 
Motor GCS ≥3 4.69 2.47-9.04 <0.001 
Center CHUV 2.13 1.04-4.35 0.038 
B OR 95% CI P 
Early EEG not reactive 21.97 5.74-84.08 <0.001 
Early EEG epileptiform 15.07 4.62-49.2 <0.001 
Late EEG non reactive 41.37 4.94-346.36 0.001 
Center CHUV 1.79 0.66-4.89 0.254 
 A: Hosmer-Lemeshow P= 0.777; B: Hosmer-Lemeshow P= 0.994. GCS= Glasgow Coma Score. 
 
Table 4: Predictors of mortality in the whole cohort. 
  Distribution Mortality 
(CPC 5) 
Accuracy 
Variable Tested  
patients 
TP FP FN TN Sensitivity 
(%) 
95% CI 
(%) 
FPR 
(%) 
95% CI 
(%) 
Pojnt 
Est. 
95% CI 
(%) 
Male gender 357 105 150 48 54 68.6 60.6-75.9 73.5 66.9-79.5   
Age > 64 357 84 75 69 129 54.9 46.7-63.0 36.8 30.1-43.8   
Noncardiac etiology 357 41 34 112 170 26.8 20.0-34.6 16.7 11.8-22.5   
Nonshockable rhyhtm 357 66 41 87 163 43.1 35.2-51.4 20.1 14.8-26.3   
Early EEG not reactive 357 108 3 45 201 70.6 62.7-77.7 1.5 0.3-4.2 86.6 82.6-90.0 
Early EEG not continuous 357 123 48 30 156 80.4 73.2-86.4 23.5 17.9-30.0   
Early EEG epileptiform 357 74 7 79 197 48.3 40.2-56.6 3.4 1.4-6.9 75.9 71.1-80.2 
Early EEG « Highly malignant » 357 105 3 48 201 68.3 60.6-75.9 1.5 0.3-4.2 85.7 81.7-89.2 
Late EEG not reactive 357 96 1 57 203 62.8 54.6-70.4 0.5 0.0-2.7 83.8 79.5-87.4 
Late EEG not continuous 357 88 18 65 186 57.5 49.2-65.5 8.8 0.5-13.6   
Late EEG epileptiform 357 85 12 68 192 55.6 47.3-63.3 5.9 3.1-10-5   
Late EEG « Highly malignant » 357 96 3 57 201 62.8 54.6-70.4 1.5 0.3-4.2 83.2 78.9-86.9 
SSEP bilaterally absent 260 60 1 63 136 48.8 39.7-58.0 0.7 0.0-4.0 75.4 69.7-80.1 
Pupillary bilaterally abnormal 355 50 4 103 198 32.7 25.3-40.7 2.0 0.5-5.0 69.9 64.8-74.6 
Corneal bilaterally abnormal 354 69 6 84 195 45.1 37.1-53.3 3.0 1.1-6.4 74.6 69.7-79.0 
Motor GCS <3 357 127 31 26 173 83.0 76.1-88.6 15.2 10.6-20.9   
Early Myoclonus 357 63 5 90 199 41.2 33.3-49.4 2.5 0.8-5.6 73.4 68.5-77.9 
NSE ≥75 µg/l 329 60 1 77 191 43.8 35.3-52.5 0.5 0.0-2.9 76.3 71.3-80.8 
TP= true positive, FP= false positive, FN= false negative, TN= true negative. CPC= cerebral 
performance category; SSEP= somatosensory evoked potentials; GCS= Glasgow Coma Score; 
NSE= neuron specific enolase. Accuracies were only calculated for items with FPR <5%. 
 
Supplementary Table1: Subset of good outcome predictors according to previously and newly 
published patients. 
 
Previously published patients (196)  Distribution Good outcome 
(CPC 1-2) 
Variable Tested  
patients 
TP FP FN TN PPV 
(%) 
95% CI 
(%) 
Early EEG reactive 196 96 40 1 59 70.6 62.2 – 78.1 
Early EEG continuous 196 85 21 12 78 80.2 71.3 – 87.3 
Early EEG not epileptiform 196 92 55 5 44 62.6 54.2 – 70.4 
Early EEG « Benign » 196 73 12 24 87 85.9 76.6 – 92.5 
Late EEG reactive 196 97 42 0 57 70.8 62.4 – 78.3 
Late EEG continuous 196 85 21 12 78 80.2 71.3 – 87.3 
Late EEG not epileptiform 196 92 50 5 49 63.4  54.9 – 71.3 
SSEP present 134 59 40 0 35 59.6 49.3 – 69.3 
Pupillary normal 194 95 70 2 27 57.6 49.7 – 65.2 
Motor GCS ≥3 196 80 26 17 73 82.4 73.4 – 89.4 
No early Myoclonus 196 94 67 3 32 58.4 50.4 – 66.1 
NSE <75 µg/l 183 92 57 0 34 61.7 53.4 – 69.6 
Newly published patients (161)  Distribution Good outcome 
(CPC 1-2) 
Variable Tested  
patients 
TP FP FN TN PPV 
(%) 
95% CI 
(%) 
Early EEG reactive 161 82 28 1 50 74.5 65.4 – 82.4 
Early EEG continuous 161 59 21 24 57 73.8 62.7 – 83.0 
Early EEG not epileptiform 161 80 45 3 33 64.0 54.9 – 72.4 
Early EEG « Benign » 161 64 10 19 68 86.5 76.5 – 93.3 
Late EEG reactive 161 82 39 1 39 67.7 58.7 – 76.0 
Late EEG continuous 161 75 37 8 41 67.0 57.4 – 75.6 
Late EEG not epileptiform 161 81 37 2 41 68.6 59.5 – 76.9 
SSEP present 126 60 40 0 26 60.0 49.7 – 69.7 
Pupillary normal 161 82 54 1 24 60.3  51.6 – 68.6 
Motor GCS ≥3 161 71 16 12 62 81.6 71.9 – 89.1 
No early Myoclonus 161 82 46 1 32 64.1 55.1 – 72.3 
NSE <75 µg/l 146 77 42 0 27 64.7 55.4 – 73.2 
 
 
 
 
 
 
 
  
Supplementary Table2: Subset of mortality predictors according to previously and newly 
published patients. 
Previously published patients (196)  Distribution Mortality 
(CPC 5) 
Variable Tested  
patients 
TP FP FN TN FPR 
(%) 
95% CI 
(%) 
Early EEG not reactive 196 59 1 23 113 0.9 0.0 - 4.8 
Early EEG not continuous 196 69 21 13 93 18.4 11.8 -26.8 
Early EEG epileptiform 196 42 5 40 109 4.4 1.4 – 9.9 
Early EEG « Highly malignant » 196 53 2 29 112 1.2 0.2 – 6.2 
Late EEG not reactive 196 57 0 25 114 0.0 0.0 - 3.2 
Late EEG not continuous 196 47 10 35 104 8.8 4.3 – 15.5 
Late EEG epileptiform 196 45 9 37 105 7.9 3.7 – 14.5 
SSEP bilaterally absent 134 34 1 27 72 1.3 0.0 – 7.4 
Pupillary bilaterally absent 194 30 2 60 110 1.8 0.2 – 6.3 
Motor GCS <3 196 67 17 15 97 14.9 8.9 - 22.8 
Early Myoclonus 196 31 4 51 110 3.5 1.0 – 8.7 
NSE ≥75 µg/l 183 34 0 41 108 0.0 0.0 - 3.4 
Newly published patients (161)  Distribution Mortality 
(CPC 5) 
Variable Tested  
patients 
TP FP FN TN FPR 
(%) 
95% CI 
(%) 
Early EEG not reactive 161 49 2 22 88 2.2 0.2 - 7.8 
Early EEG not continuous 161 54 27 17 63 30.0 20.8 – 40.6 
Early EEG epileptiform 161 32 2 39 88 2.2 0.2 – 7.8 
Early EEG « highly malignant » 161 52 1 19 89 1.1 0.0 – 6.0 
Late EEG not reactive 161 39 1 32 89 1.1 0.0 – 6.0 
Late EEG not continuous 161 41 8 30 82 8.9 3.9 -16.8 
Late EEG epileptiform 161 40 3 31 87 3.3 0.7 – 9.4 
SSEP bilaterally absent 126 26 0 36 64 0.0 0.0 - 5.6 
Pupillary bilaterally absent 161 20 2 43 88 2.2 0.2 – 7.8 
Motor GCS <3 161 60 14 11 76 15.5 8.8 24.7 
Early Myoclonus 161 32 1 39 89 1.1 0.0 – 6.0 
NSE ≥75 µg/l 146 26 1 36 83 1.2 0.0 – 6.5 
 
 
 
 
TP= true positive, FP= false positive, FN= false negative, TN= true negative. CPC= cerebral 
performance category; SSEP= somatosensory evoked potentials; GCS= Glasgow Coma Score; 
NSE= neuron specific enolase.  
 
